CASTLEMAN PETER M 4

What Happened
Peter M. Castleman, a director of Caris Life Sciences (CAI), was issued 5,509 shares on Feb 26, 2026 at an effective price of $20.06 per share — a grant/award valued at approximately $110,511. This was an issuance in lieu of cash payment for 2025 board retainer fees (an award/acquisition, not an open-market buy).

Key Details

• Transaction date and price: 2026-02-26 at $20.06 per share. Total value ≈ $110,511.
• Shares issued: 5,509 shares (code A — award/grant/acquisition).
• Shares owned after transaction: Not disclosed in this filing.
• Filing: Form 4 filed 2026-02-27 (appears timely, filed the next day).
• Notable footnotes:
  • F1: Shares were issued in lieu of cash compensation for 2025 board retainer fees; the number of shares was determined using the 10-trading-day VWAP through Feb 25, 2026.
  • F2: Mr. Castleman is a manager of CLS-PF-SPE Manager, LLC, which manages CLS-PF-SPE, LLC; he disclaims beneficial ownership except to the extent of his pecuniary interest.

Context
This was a routine equity issuance for board compensation, common for non-employee directors. Because the shares were issued in lieu of cash (per F1), the transaction reflects compensation mechanics rather than a market-based buy/sell decision; the F2 disclosure indicates the shares may be associated with an entity he manages and limits claimed beneficial ownership.